Featured Articles
Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases” focused on ocular and central nervous system (CNS) indications. It is understood that Regeneron will pay a $400 million upfront payment to Alnylam and will […]
Read full storyThe EU Clinical Trials Register (EUCTR) indicates that the compliance with the EU rules “have been poor overall”
A new automated tool, the “EU TrialsTracker”, has been launched by several academic researchers working at the Evidence-Based Medicine Data Lab, University of Oxford, UK. The tool provides an automated software algorithm designed to identify commercial and non-commercial clinical trial sponsors with the best and worst record for sharing trial results. The underlying premise is […]
Read full storyOptogenetics research uses medium-wavelength cone opsin to re-engineer retinal ganglion cells for retinitis pigmentosa
Researchers at the University of Berkeley have reported that the vertebrate medium wavelength cone opsin (MW-opsin) may be used to overcomes limitations to support vision in dim light in a mouse model for retinitis pigmentosa (RP). The study will be used to develop optogenetic therapy to overcome downstream retinal neurons where rod photoreceptors may have […]
Read full story